Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> CLSA Raises Shanghai Pharmaceuticals (02607.HK) TP to HKD15.2, Rating Outperform
Recommend 2 Positive 2 Negative 0 |
||||
|
||||
|
CLSA issued a research report stating that Shanghai Pharmaceuticals (02607.HK) recorded revenue of RMB283.6 billion in FY2025, up 3% YoY, while net profit reached RMB5.73 billion, up 25.7% YoY, both broadly in line with market expectations. Traditional Chinese medicine has remained the core driver of the companys manufacturing business, and the company will continue to prioritize the development of innovative drug R&D to drive growth. The broker raised its TP from HKD14.2 to HKD15.2 and maintained an Outperform rating. (ca/j) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
